Protecting the Public's health Through the Application Integrity Policy

August 2010

FDA's recent use of the Application Integrity Policy (AIP), most notably in the ongoing Ranbaxy matter, has created interest in the policy. The article discusses actions CDER's Office of Compliance is currently undertaking to raise awareness of the AIP and establish the Office of Compliance as CDER’s clearing-house for integrity issues. The article reviews a current AIP case and discusses how the use of the AIP can protect public health.


FDLI's policy regarding the Food and Drug Law Journal online is: Only the Table of Contents and article abstracts for each issue will be posted to our website. Those visitors wishing to obtain a full text version of a particular article, or a copy of an entire issue, may contact FDLI’s Customer Service Department by e-mail at service@fdli.org. Your purchase will be processed quickly, and at reasonable rates.

Any questions or concerns regarding this policy change should be directed to
Michael Levin-Epstein
, Editor-in-Chief.